Table 1.

Demographics and patient characteristics for the validation cohort

Characteristic	Validation cohort (n = 270)
Age, y
Mean (SD)	61.96 (7.06)
Range	37.00–79.00
Presurgery PSA, ng/mL
Mean (SD)	7.06 (5.68)
Range	0.80–52.4
PSA unknown, no. (%)	36 (13.3)
Gleason score at RP, no. (%)
≤6	110 (41)
7	120 (44)
≥8	40 (15)
pT stage, no. (%)
2	221 (82)
3	49 (18)
Surgical margin, no. (%)
Negative	204 (76)
Positive	66 (24)
Salvage therapy after BCF, no. (%)
No	225 (83)
Yes	45 (17)
BCF event, no.
No	195
Yes	75
Time to BCF event, y, median (range)	4.28 (0.70–11.54)
Follow-up time, no BCF event, y, median (range)	9.43 (0.53–13.49)
Metastasis event, no.
No	253
Yes	17
Time to metastasis event, y, median (range)	7.54 (2.09–12.96)
Follow-up time, no metastasis event, y, median (range)	10.35 (0.47–14.67)
Death (all-cause) event, no.
No	229
Yes	41
Time to death (all-cause), y, median (range)	9.84 (1.41–13.13)
Follow-up time, no death event, y, median (range)	12.74 (10.74–14.18)